ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35049
-0,49%
Bitcoin
66.234,63
0,35%
Brent Oil
82,275
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Europa
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) Notícias

ARGX Argen X SE

360,90
2,30 (0,64%)
14 Jun 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Argen X SE ARGX Euronext Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
2,30 0,64% 360,90 12:40:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
358,60 357,40 366,10 360,90 358,60
mais cotações »

Notícias Recentes

Data Hora Fonte Título
04/06/202402:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
09/05/202402:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
07/05/202418:30GLOBEargenx announces results of Annual General Meeting of..
07/05/202402:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/05/202402:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/04/202402:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/03/202403:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/03/202417:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/03/202403:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/03/202418:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/02/202403:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/02/202403:00GLOBEargenx to Present at Upcoming Investor Conferences
22/02/202403:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/02/202403:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/01/202403:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/01/202403:00GLOBEargenx Highlights 2024 Strategic Priorities
02/01/202403:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202303:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202303:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202309:40GLOBEargenx Announces European Commission Approval of..
01/11/202303:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202303:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202302:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/09/202302:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/09/202302:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/08/202302:00GLOBEargenx to Present at Upcoming Investor Conferences
27/07/202302:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/07/202317:30GLOBEargenx announces closing of global offering
20/07/202302:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/07/202318:58GLOBEargenx announces full exercise of underwriters’ option to..
18/07/202322:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/07/202317:01GLOBEargenx announces launch of proposed global offering
17/07/202302:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/06/202310:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
20/06/202319:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/06/202302:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..

Seu Histórico Recente

EU
ARGX
Argen X
NYSE
JNJ.WD
Johnson and Johnson
BIT
WCLABO
Clabo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados